Kodiak Sciences Inc.
KOD
株式のランク
#3086
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
株価
$93.69
時価総額
$5.89B
変化（1日）
2.56%
変化（1年）
429.32%
国
US
取引 Kodiak Sciences Inc. (KOD)
カテゴリー
Healthcare
Kodiak Sciences Inc.（KOD）の株式分割履歴
Kodiak Sciences Inc.株（シンボル：KOD）は合計で1回の株式分割を実施しました。
最新の株式分割はFeb 23, 2022に行われました。
Feb 23, 2022より前に購入されたKOD株は、現在5KOD株に相当します。
最新の株式分割はFeb 23, 2022に行われました。
Feb 23, 2022より前に購入されたKOD株は、現在5KOD株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
